HTDDSFMT

HIGH THROUGHPUT DRUG DISCOVERY STUDIES FOR MENINGIOMA THERAPEUTICS

Coordinatore	MEDIZINISCHE UNIVERSITAET WIEN    more  Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Arnold Cognome: Pollak Email: send email Telefono: +43 1 40 400 5572 Fax: +43 1 40 400 3296
Nazionalità Coordinatore	Austria [AT]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-CIG
Funding Scheme	MC-CIG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-08-01   -   2015-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	MEDIZINISCHE UNIVERSITAET WIEN  Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Arnold Cognome: Pollak Email: send email Telefono: +43 1 40 400 5572 Fax: +43 1 40 400 3296	AT (WIEN)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Meningiomas arise from arachnoid cells and account for approximately 30% of all primary intracranial tumors. Most meningiomas (80-90%) are categorized as benign tumors (WHO grade I), with the remaining 10-20% being atypical (WHO grade II) or malignant (WHO grade III). Gross total resection offers the best chance of cure. Unfortunately, for meningiomas that are difficult to access, complete resection often cannot be achieved safely. In patients whose tumors are incompletely resected, recurrence is common, approaching 70% with 10–15 years of follow-up; in the case of atypical and malignant meningiomas, the time to recurrence is shorter and long-term survival rates are low. There are no established treatments for recurrent meningioma when surgical and radiation options are exhausted and current experience with chemotherapy and various targeted therapies is disappointing. Therefore, novel therapeutic strategies which can be combined with surgery need to be developed to control tumor growth. This application is directed towards developing new therapeutic options for meningiomas in a high throughput small (HTS) molecule screening system using the NINDS custom collection II library consisting of 1040 drugs and bioactive compounds, FDA-approved, which cross the blood-brain barrier (BBB). In our primary screening, we identified drug candidates that were specifically toxic to meningioma cells. These promising preliminary data stimulate us to further evaluate the effect of these candidates on meningioma tumor models in mice and explore the possible molecular mechanism(s) of tumor inhibition mediated by these candidate drugs.'